Immunogenicity and Safety Study of 1 and 2 Doses of Meningococcal Vaccine MenACWY-TT in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13® Vaccine

A Phase III, Randomised, Open, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity and Persistence of 1 and 2 Doses of Meningococcal Conjugate Vaccine MenACWY-TT in Toddlers (After 1 Month and up to 5 Years) and to Demonstrate Non-Inferiority of Co-Administration of MenACWY-TT and 13-Valent Pneumococcal Conjugate Vaccine Prevenar 13® Versus Separate Administration of the 2 Vaccines

Category & Conditions: Vaccine-related Conditions

Medicine: Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) PREVNAR 13(PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE [DIPHTHERIA CRM197 PROTEIN])

ClinicalTrials.gov Identifier (NCT): NCT01939158

Protocol ID: C0921003

Print Download

Open Plain Language Summary Result: Click here